A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
TNBC
Interventions
DRUG

PM8002

IV infusion

DRUG

nab-paclitaxel

IV infusion

Trial Locations (8)

Unknown

The First Affiliated Hospital of Chongqing Medical University, Chongqing

Affiliated Cancer Hospital of Harbin Medical University, Harbin

Jiangsu Province Hospital, Nanjing

Nanchang Third Hospital, Nanchang

The first ward of breast Surgery, Shandong Cancer Hospital, Jinan

Fudan University Shanghai Cancer Center, Shanghai

Yibin Second People's Hospital, Yibin

Tian Jin Medicial University Cancer Institute&Hospital, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biotheus Inc.

INDUSTRY